At 68 weeks, participants taking 2.4 mg of semaglutide (Wegovy) weekly lost 15.8% of their body weight, compared to 6.4% for participants taking 3 mg of liraglutide (Saxenda)
and screen for affective disorders which can influence healthfulness of dietary choices and changes in calorie intake [121]
Both peptides are designed for once-weekly subcutaneous dosing and possess extended half-lives (approximately 5 days for Tirzepatide and slightly longer for Retatrutide due to structural modifications)
Administration: Once-weekly injection
They create fake social media profiles, anything and everything, to showcase that they're real, but they're not." Carter says their analysis reveals a wave of pharmaceutical scams
At week 112, the full-dose group remained down 22.4% from baseline, while the 5 mg group remained down 17.0%